[go: up one dir, main page]

MX2018002514A - Citotoxinas modificadas y su uso terapeutico. - Google Patents

Citotoxinas modificadas y su uso terapeutico.

Info

Publication number
MX2018002514A
MX2018002514A MX2018002514A MX2018002514A MX2018002514A MX 2018002514 A MX2018002514 A MX 2018002514A MX 2018002514 A MX2018002514 A MX 2018002514A MX 2018002514 A MX2018002514 A MX 2018002514A MX 2018002514 A MX2018002514 A MX 2018002514A
Authority
MX
Mexico
Prior art keywords
description provides
small molecule
cytotoxins
modified
portions
Prior art date
Application number
MX2018002514A
Other languages
English (en)
Other versions
MX380314B (es
Inventor
E Callmann Cassandra
P Thompson Matthew
L M Leguyader Clare
C Gianneschi Nathan
A Bertin Paul
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2018002514A publication Critical patent/MX2018002514A/es
Publication of MX380314B publication Critical patent/MX380314B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente descripción en general proporciona compuestos útiles para tratar cáncer. En algunos aspectos, la descripción proporciona citotoxinas de molécula pequeña que se modifican químicamente para incluir una o más porciones que incluyen porciones hidrófobas. En algunas modalidades, la descripción proporciona citotoxinas de molécula pequeña que se modifican químicamente con porciones que contienen ácido graso. En algunos aspectos, la descripción proporciona composiciones, tal como composiciones farmacéuticas, que incluyen estas citotoxinas de molécula pequeña modificadas y una proteína. En algunas modalidades, la proteína es albúmina o un compuesto imitador de albúmina. Además la descripción proporciona varios usos de estos compuestos y composiciones.
MX2018002514A 2015-09-22 2016-09-21 Citotoxinas modificadas y su uso terapeutico. MX380314B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222059P 2015-09-22 2015-09-22
PCT/US2016/052829 WO2017053391A1 (en) 2015-09-22 2016-09-21 Modified cytotoxins and their therapeutic use

Publications (2)

Publication Number Publication Date
MX2018002514A true MX2018002514A (es) 2018-08-15
MX380314B MX380314B (es) 2025-03-12

Family

ID=58276138

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002514A MX380314B (es) 2015-09-22 2016-09-21 Citotoxinas modificadas y su uso terapeutico.

Country Status (14)

Country Link
US (3) US10023581B2 (es)
EP (1) EP3353159A4 (es)
JP (1) JP2018527360A (es)
KR (1) KR20180045001A (es)
CN (1) CN108368075A (es)
AU (1) AU2016326392B2 (es)
CA (1) CA2998528A1 (es)
HK (1) HK1254461A1 (es)
IL (1) IL257932A (es)
MX (1) MX380314B (es)
MY (1) MY193776A (es)
RU (1) RU2721949C2 (es)
WO (1) WO2017053391A1 (es)
ZA (1) ZA201801482B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193776A (en) 2015-09-22 2022-10-27 Univ California Modified cytotoxins and their therapeutics use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
SG11201908771YA (en) * 2017-03-22 2019-10-30 Univ California Modified oligonucleotides and therapeutic uses thereof
WO2021007322A1 (en) * 2019-07-09 2021-01-14 Northwestern University Methods of using modified cytotoxins to treat cancer
IT202100025172A1 (it) * 2021-09-30 2023-03-30 Indena Spa Processo per la preparazione di derivati tassanici
KR20250057244A (ko) 2023-10-20 2025-04-29 (주)블루엔씨 고정밀 3d 프린팅 기반 금형 제작 방법 및 장치

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
AU6803494A (en) * 1993-06-07 1995-01-03 British Technology Group Limited Anticancer compounds
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
AU735205B2 (en) 1997-05-16 2001-07-05 Commonwealth Scientific And Industrial Research Organisation Vaccine and assay
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
NO319551B1 (no) 2003-07-04 2005-08-29 Thia Medica As Proteinmateriale fra enkeltceller
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
US20070203058A1 (en) 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
RU2340616C2 (ru) * 2003-10-29 2008-12-10 Сонус Фармасьютикалз, Инк. Токоферол-модифицированные терапевтические лекарственные соединения
GB0412181D0 (en) * 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2006030217A2 (en) * 2004-09-15 2006-03-23 Drug Discovery Laboratory As Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
WO2007075825A2 (en) * 2005-12-20 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
DE112009000300T5 (de) 2008-02-08 2011-01-20 Aileron Therapeutics, Inc., Cambridge Therapeutische Peptidomimetische Makrocyclen
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
US20100240883A1 (en) 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
WO2010112942A1 (en) 2009-04-02 2010-10-07 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
EP2521446A2 (en) 2010-01-06 2012-11-14 The University of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
WO2011101261A2 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Purification method
WO2011143201A2 (en) * 2010-05-10 2011-11-17 The Regents Of The University Of California Ratiometric combinatorial drug delivery
EP2392324A1 (en) * 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
EP3028720A1 (en) 2010-09-28 2016-06-08 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
EP2624869A4 (en) * 2010-10-08 2015-11-04 Univ Virginia Commonwealth PRODRUGS USING A CONTAINER CONTROLLED ABSORPTION MECHANISM
KR20140057414A (ko) 2011-06-22 2014-05-12 바이옴 바이오사이언스 피브이티. 엘티디. 컨쥬게이트계 항진균 및 항세균 프로드러그
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
KR101435261B1 (ko) * 2012-07-23 2014-09-02 아주대학교산학협력단 항암제-링커-알부민 결합체, 이의 제조방법 및 상기 결합체를 포함하는 약물 전달용 조성물
AU2013350311B2 (en) * 2012-11-21 2018-03-22 The University Of Sydney Omega-3 analogues
US9962452B2 (en) * 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
WO2014201026A2 (en) * 2013-06-10 2014-12-18 Cedars-Sinai Medical Center Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof
CN105934257B (zh) 2013-12-06 2020-10-09 韩捷 用于含氮和羟基的药物的生物可逆引入基团
SI3229810T1 (sl) * 2014-11-17 2021-01-29 Cellestar Biosciences, Inc. Analogi fosfolipidnega etra kot vehikli zdravil, usmerjenih proti raku
CN104478813A (zh) * 2014-12-20 2015-04-01 苏州博源医疗科技有限公司 5-氟尿嘧啶衍生物、5-氟尿嘧啶免疫原及其抗体与5-氟尿嘧啶检测试剂盒
US10286079B2 (en) * 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
MY193776A (en) * 2015-09-22 2022-10-27 Univ California Modified cytotoxins and their therapeutics use
US20210137957A1 (en) * 2017-03-22 2021-05-13 The Regents Of The University Of California Modified anthracycline compounds and their therapeutic use
WO2018175595A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified histone deacetylase inhibitors and uses thereof
WO2018175601A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified platinum compounds and therapeutic uses thereof
JP2020517584A (ja) * 2017-04-27 2020-06-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 修飾ｍｒｉ造影剤およびその使用

Also Published As

Publication number Publication date
US20180222915A1 (en) 2018-08-09
CN108368075A (zh) 2018-08-03
KR20180045001A (ko) 2018-05-03
RU2721949C2 (ru) 2020-05-25
JP2018527360A (ja) 2018-09-20
AU2016326392B2 (en) 2021-02-11
US20170080094A1 (en) 2017-03-23
CA2998528A1 (en) 2017-03-30
MY193776A (en) 2022-10-27
MX380314B (es) 2025-03-12
HK1254461A1 (zh) 2019-07-19
US20210047338A1 (en) 2021-02-18
IL257932A (en) 2018-06-03
EP3353159A4 (en) 2019-03-27
US10654864B2 (en) 2020-05-19
RU2018107843A3 (es) 2019-11-28
AU2016326392A1 (en) 2018-03-22
US10023581B2 (en) 2018-07-17
ZA201801482B (en) 2021-07-28
EP3353159A1 (en) 2018-08-01
RU2018107843A (ru) 2019-10-25
WO2017053391A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
CL2017002650A1 (es) Compuestos novedosos
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
CL2017002122A1 (es) Heterociclos bicíclicos como inhibidores de fgfr4
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
UY35813A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2016002571A (es) Regulador de ph de transduccion.
CR20160229A (es) Inhibidires de bromodominio
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016002077A (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
DOP2016000253A (es) Nuevos compuestos
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY37236A (es) Ésteres de oxaborol y sus usos
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos